赛诺菲：瑞达普在华获批 一年四次给药降低80%甘油三酯水平与急性胰腺炎发生风险

Core Viewpoint - Sanofi announced the approval of its innovative drug, Risdiplam (Praluent), by the National Medical Products Administration (NMPA) for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS) [1] Group 1: Drug Approval and Indication - Risdiplam is the first small interfering RNA (siRNA) drug targeting the innovative APOC3 (apolipoprotein C-III) mRNA [1] - The drug is indicated for use in conjunction with dietary control to manage triglyceride levels in FCS patients [1] Group 2: Clinical Efficacy - Risdiplam can reduce fasting triglyceride levels by 80% compared to baseline in FCS patients [1] - The incidence of acute pancreatitis is reduced by 80% compared to placebo [1] - The drug requires administration only four times a year, addressing the current lack of treatment options for FCS in China [1]